Importer of Controlled Substances Application: Fisher Clinical Services, Inc., 60864 [2014-24081]
Download as PDF
<![CDATA[
60864
Federal Register / Vol. 79, No. 195 / Wednesday, October 8, 2014 / Notices
asabaliauskas on DSK5VPTVN1PROD with NOTICES
The Commission advises the
Secretary and the NPS on matters
relating to the management and
development of Acadia National Park,
including but not limited to the
acquisition of lands and interests in
lands (including conservation
easements on islands) and the
termination of rights of use and
occupancy.
The Commission is composed of 16
members appointed by the Secretary, as
follows: (a) Three members at large; (b)
three members appointed from among
individuals recommended by the
Governor of Maine; (c) four members
appointed from among individuals
recommended by each of the four towns
on the island of Mount Desert; (d) three
members appointed from among
individuals recommended by each of
the three Hancock County mainland
communities of Gouldsboro, Winter
Harbor, and Trenton, and; (e) three
members appointed from among
individuals recommended by each of
the three island towns of Cranberry
Isles, Swans Island, and Frenchboro.
Members of the Commission will
receive no pay, allowances, or benefits
by reason of their service on the
Commission. However, while away from
their homes or regular places of
business in the performance of services
for the Commission as approved by the
Designated Federal Officer, members
will be allowed travel expenses,
including per diem in lieu of
subsistence, in the same manner as
persons employed intermittently in
Government service are allowed such
expenses under 5 U.S.C. 5703.
Individuals who are Federally
registered lobbyists are ineligible to
serve on all FACA and non-FACA
boards, committees, or councils in an
individual capacity. The term
‘‘individual capacity’’ refers to
individuals who are appointed to
exercise their own individual best
judgment on behalf of the government,
such as when they are designated
Special Government Employees, rather
than being appointed to represent a
particular interest.
Seeking Nominations for Membership
We are seeking nominations for
commission members in the following
category: Members at large.
Nominations should include a resume
providing an adequate description of the
nominee’s qualifications, including
information that would enable the
Department of the Interior to make an
informed decision regarding meeting the
membership requirements of the
Commission and permit the Department
to contact a potential member.
VerDate Sep<11>2014
17:27 Oct 07, 2014
Jkt 235001
Members are appointed by the
Secretary for a term not to exceed three
years. The terms of the three members
at large of the Commission expire on
September 28, 2014. The Commission
last met on June 2, 2014, and usually
meets three times per year, generally in
June, September, and February.
Meetings may take place at such times
as designated by the Designated Federal
Officer. Members are expected to make
every effort to attend all meetings.
Members may not appoint deputies or
alternates.
Controlled substance
Dated: September 26, 2014.
Alma Ripps,
Chief, Office of Policy.
[FR Doc. 2014–24044 Filed 10–7–14; 8:45 am]
BILLING CODE 4310–EE–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before November 7, 2014. Such
persons may also file a written request
for a hearing on the application
pursuant to 21 CFR 1301.43 on or before
November 7, 2014.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of importers,
of controlled substances (other than
final orders in connection with
suspension, denial, or revocation of
registration) has been redelegated to the
DATES:
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Deputy Assistant Administrator of the
DEA Office of Diversion Control
(‘‘Deputy Assistant Administrator’’)
pursuant to section 7 of 28 CFR part 0,
subpart R, App.
In accordance with 21 CFR
1301.34(a), this is notice that on
December 13, 2013, Fisher Clinical
Services, Inc., 700A–C Nestle Way,
Breinigsville, Pennsylvania 18031–1522
applied to be registered as an importer
of the following basic classes of
controlled substances:
Methylphenidate (1724) ................
Levorphanol (9220) ......................
Noroxymorphone (9668) ..............
Tapentadol (9780) ........................
Schedule
II
II
II
II
The company plans to import the
listed substances for analytical research,
testing, and clinical trials. This
authorization does not extend to the
import of a finished FDA approved or
non-approved dosage form for
commercial distribution in the United
States.
The company plans to import an
intermediate form of tapentadol (9780)
to bulk manufacture tapentadol for
distribution to its customers.
Dated: October 1, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014–24081 Filed 10–7–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration: Alkermes Gainesville
LLC
ACTION:
Notice of registration.
Alkermes Gainesville LLC
applied to be registered as an importer
of a basic class of controlled substance.
The DEA grants Alkermes Gainesville
LLC registration as an importer of this
controlled substance.
SUPPLEMENTARY INFORMATION: By notice
dated June 10, 2014, and published in
the Federal Register on June 17, 2014,
79 FR 34551, Alkermes Gainesville LLC,
1300 Gould Drive, Gainesville, Georgia
30504, applied to be registered as an
importer of a certain basic class of
controlled substance. No comments or
objections were submitted for this
notice.
The Drug Enforcement
Administration (DEA) has considered
SUMMARY:
E:\FR\FM\08OCN1.SGM
08OCN1
]]>Agencies
[Federal Register Volume 79, Number 195 (Wednesday, October 8, 2014)]
[Notices]
[Page 60864]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-24081]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Fisher Clinical
Services, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.34(a) on or before November 7, 2014. Such persons may also file a
written request for a hearing on the application pursuant to 21 CFR
1301.43 on or before November 7, 2014.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODW,
8701 Morrissette Drive, Springfield, Virginia 22152. Request for
hearings should be sent to: Drug Enforcement Administration, Attention:
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
importers, of controlled substances (other than final orders in
connection with suspension, denial, or revocation of registration) has
been redelegated to the Deputy Assistant Administrator of the DEA
Office of Diversion Control (``Deputy Assistant Administrator'')
pursuant to section 7 of 28 CFR part 0, subpart R, App.
In accordance with 21 CFR 1301.34(a), this is notice that on
December 13, 2013, Fisher Clinical Services, Inc., 700A-C Nestle Way,
Breinigsville, Pennsylvania 18031-1522 applied to be registered as an
importer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Methylphenidate (1724)..................... II
Levorphanol (9220)......................... II
Noroxymorphone (9668)...................... II
Tapentadol (9780).......................... II
------------------------------------------------------------------------
The company plans to import the listed substances for analytical
research, testing, and clinical trials. This authorization does not
extend to the import of a finished FDA approved or non-approved dosage
form for commercial distribution in the United States.
The company plans to import an intermediate form of tapentadol
(9780) to bulk manufacture tapentadol for distribution to its
customers.
Dated: October 1, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-24081 Filed 10-7-14; 8:45 am]
BILLING CODE 4410-09-P
